VEGFA peptide (ab46160)
Key features and details
- Purity: > 90% HPLC
- Suitable for: Blocking
Description
-
Product name
VEGFA peptide
See all VEGFA proteins and peptides -
Purity
> 90 % HPLC. -
Accession
-
Animal free
No -
Nature
Synthetic -
-
Species
Human
-
-
Description
Human VEGFA peptide
Associated products
-
Corresponding Antibody
Specifications
Our Abpromise guarantee covers the use of ab46160 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
Applications
Blocking - Blocking peptide for Anti-VEGFA antibody (ab46154)
-
Form
Liquid -
Additional notes
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
- If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
- Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
- Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
- Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use. -
Concentration information loading...
Preparation and Storage
-
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
General Info
-
Alternative names
- Folliculostellate cell-derived growth factor
- Glioma-derived endothelial cell mitogen
- MGC70609
see all -
Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. -
Tissue specificity
Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. -
Involvement in disease
Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. -
Sequence similarities
Belongs to the PDGF/VEGF growth factor family. -
Cellular localization
Secreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. - Information by UniProt
Images
-
All lanes : Anti-VEGFA antibody (ab46154) at 0.5 µg/ml
Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
Lane 2 :Jurkat whole cell lysate (ab7899)
Lane 3 :A-431 whole cell lysate (ab7909)
Lane 4 :HEK-293 whole cell lysate (ab7902)
Lane 5 : Hep G2 whole cell lysate (ab7900)
Lane 6 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate
Lane 7 : SHSY-5Y (Human neuroblastoma cell line) Whole Cell Lysate
Lane 8 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate withVEGFA peptide (ab46160) at 1 µg/ml
Lane 9 :Jurkat whole cell lysate (ab7899) with VEGFA peptide (ab46160) at 1 µg/ml
Lane 10 :A-431 whole cell lysate (ab7909) with VEGFA peptide (ab46160) at 1 µg/ml
Lane 11 :HEK-293 whole cell lysate (ab7902) with VEGFA peptide (ab46160) at 1 µg/ml
Lane 12 : Hep G2 whole cell lysate (ab7900) withVEGFA peptide (ab46160) at 1 µg/ml
Lane 13 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate withVEGFA peptide (ab46160) at 1 µg/ml
Lane 14 : SHSY-5Y (Human neuroblastoma cell line) Whole Cell Lysate withVEGFA peptide (ab46160) at 1 µg/ml
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : IRDye 680 Conjugated Goat Anti-Rabbit IgG (H+L) at 1/10000 dilution
Performed under reducing conditions.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (3)
ab46160 has been referenced in 3 publications.
- Dong D et al. microRNA-646 inhibits angiogenesis of endothelial progenitor cells in pre-eclamptic pregnancy by targeting the VEGF-A/HIF-1a axis. Exp Ther Med 20:1879-1888 (2020). PubMed: 32782496
- Hu XM et al. Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer. Anesthesiology 131:1125-1147 (2019). PubMed: 31567367
- Han B et al. Effects of tripterygium glycosides on restenosis following endovascular treatment. Mol Med Rep 13:4959-68 (2016). PubMed: 27108914